1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Malignant Neoplasms: new trials by email Literature Review of Malignant Neoplasms trials Research Report on Malignant Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) Belzutifan, Nivolumab, Lenvatinib - Von Hippel-Lindau Disease, Malignant Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 450 | 2026-03-23 | 2026-10-21 |
Neoplasms (1) · von Hippel-Lindau Disease (1)
Abnormalities, Multiple (1) · Angiomatosis (1) · Cardiovascular Diseases (1) · Ciliopathies (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Nervous System Diseases (1) · Neurocutaneous Syndromes (1) · Vascular Diseases (1)
Nivolumab (1) · belzutifan (1) · cabozantinib (1) · lenvatinib (1)
Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Hungary (1) · Israel (1) · Japan (1) · Netherlands (1) · New Zealand (1) · Poland (1)
2025 (1)